$SION News
Last published 3d ago
- 3d agoSIONSionna Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 3d agoSIONSionna Therapeutics Reports Third Quarter 2026 Financial ResultsGlobeNewswireAdvancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027
- 3d agoSIONGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - SIONNA THERAPEUTICS INCEarnings Call TranscriptsAnnual Guggenheim Healthcare Innovation Conference. My name is Yatin Suneja, one of the senior biotech analysts here at the firm. It is my pleasure to welcome our next presenting company, Siona. We have a few executives
- 1w agoSIONSionna Therapeutics to Participate in Upcoming November 2026 Investor ConferencesGlobeNewswireWALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today announced
- 1mo agoSIONSionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis ConferenceGlobeNewswirePreviously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial New preclinical data evaluating NBD1 stabilizers in
- 1mo agoSIONSionna Announces Plans to Advance Dual Combination and PreciSION CF Learnings - SIONNA THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, and welcome to the CUNA Therapeutics Conference Call at this time. All participants are on a listen-only mode. After today's presentation, there will be an opportunity to ask questions. To enter the queue
- 1mo agoSIONSionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept TrialGlobeNewswirePost hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity Dual combination Phase 2a trial expected to
- 2mo agoSIONRobbins LLP Reminds Investors it is Investigating Sionna Therapeutics for Potential Securities ViolationsGlobeNewswireSAN DIEGO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ:SION) to determine whether certain Sionna Therapeutics officers and directors violated
- 2mo agoSIONRobbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna TherapeuticsPR NewswireShareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers ...
- 2mo agoSIONRobbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for InformationBusiness WireShareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ:SION) to determine whether certain Sionna Therapeutics officers and directors violated securities laws and breached fiduciary duties
- 3mo agoSIONSionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate UpdateGlobeNewswireSION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard of care Potential
- 3mo agoSIONSionna Therapeutics Reports Second Quarter 2026 Financial ResultsGlobeNewswirePreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026 Phase 1 trial evaluating NBD1 stabilizer SION-451 in
- 5mo agoSIONSionna Therapeutics, Inc. Jefferies Global Healthcare Conference in New York - SIONNA THERAPEUTICS INCEarnings Call TranscriptsHi, everyone. My name is AJ. Welcome to the Jeffries Healthcare Conference. It is my pleasure to introduce Mike Clunin of Siona Therapeutics. Thanks, AJ. Good afternoon, everyone, it's a pleasure to be with you. Nice to
- 5mo agoSIONSionna Therapeutics to Participate in Upcoming June 2026 Investor ConferencesGlobeNewswireWALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 6mo agoSIONSionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 6mo agoSIONSionna Therapeutics Reports First Quarter 2026 Financial ResultsGlobeNewswireEnrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of
- 6mo agoSIONSionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic FibrosisGlobeNewswireWALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 7mo agoSIONSionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation SymposiumGlobeNewswireWALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 8mo agoSIONSionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireOngoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated in mid-2026
- 8mo agoSIONSionna Therapeutics to Participate in Upcoming March 2026 Investor ConferencesGlobeNewswireWALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 9mo agoSIONSionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026GlobeNewswireWALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 10mo agoSIONSionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 11mo agoSIONSionna Therapeutics to Participate in Upcoming December Investor ConferencesGlobeNewswireWALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 1y agoSIONSionna Therapeutics Reports Third Quarter 2025 Financial ResultsGlobeNewswireInitiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis Successfully completed drug-drug interaction study to
- 1y agoSIONSionna Therapeutics to Participate in Upcoming November Investor ConferencesGlobeNewswireWALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 1y agoSIONSionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis ConferenceGlobeNewswirePhase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets New preclinical data show that NBD1 stabilizers
- 1y agoSIONSionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic FibrosisGlobeNewswireSION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION),
- 1y agoSIONSionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis ConferenceGlobeNewswireWALTHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 1y agoSIONSionna Therapeutics, Inc. (SION) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Earnings Call Transcripts
- 1y agoSIONSionna Therapeutics Appoints Caroline Stark Beer as Chief Business OfficerGlobeNewswireWALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 1y agoSIONSionna Therapeutics to Participate in Upcoming September Investor ConferencesGlobeNewswireWALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 1y agoSIONSionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic FibrosisGlobeNewswireWALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 1y agoSIONSionna Therapeutics Reports Second Quarter 2025 Financial ResultsGlobeNewswireAnnounced positive Phase 1 data for SION-719 and SION-451 demonstrating both first-in-class NBD1 stabilizers were generally well tolerated and exceeded pharmacokinetic targets Initiation of Phase 2a proof-of-concept
- 1y agoSIONSionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE ModelGlobeNewswireData featured in oral presentation and poster session at 48th European Cystic Fibrosis Conference WALTHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage
- 1y agoSIONSionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic FibrosisGlobeNewswireSION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to
- 1y agoSIONSionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 1y agoSIONSionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis ConferenceGlobeNewswireWALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF)
- 1y agoSIONSionna Therapeutics Reports First Quarter 2025 Financial ResultsGlobeNewswirePhase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated Phase 1 topline data anticipated this quarter On track to initiate Phase 2a proof-of-concept
- 1y agoSIONSionna Therapeutics to Present at The Citizens Life Sciences Conference 2025GlobeNewswireWALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis
- 1y agoSIONSionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswirePhase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in
- 1y agoSIONSionna Therapeutics to Present at the 45th Annual TD Cowen Health Care ConferenceGlobeNewswireBOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by
- 1y agoSIONSionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireBOSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by
- 1y agoSIONSionna Therapeutics Prices Upsized Initial Public OfferingGlobeNewswireBOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by